Manufacturing

Articles

Bio-Rad introduces CHT Ceramic Hydroxyapatite XT media and Nuvia HP-Q resin resin for process protein purification.

Chromatography Resin Designed to Boost Process-Scale Productivity

The new drug, Onpattro (patisiran), by Alnylam Pharmaceuticals, is in a new class of drugs called small interfering ribonucleic acid (siRNA) treatment.

FDA Approves First-of-its-Kind RNA Therapy

The media, by Tosoh Bioscience, is composed of calcium and phosphate buffers and offers mixed-mode properties for biomolecule purification.

Hydroxyapatite Chromotography Media Offers Enhanced Biomolecule Purification

Moderna’s new manufacturing plant in Norwood, MA gives the company capacity for preclinical and Phase I and II clinical manufacturing for its mRNA development candidates, including personalized cancer vaccines.

Moderna Opens Manufacturing Site for mRNA Therapeutics

The new company will develop proprietary RNA-based therapeutics and will provide broad lentiviral development and manufacturing expertise and support.

Vectalys, FlashCell Merge to Form Gene Therapy Company

The agreement follows the recent opening of WuXi STA's oligonucleotide R&D labs in China and the US.

WuXi STA and Regulus Collaborate on microRNA Development and Manufacturing

The companies aim to discover and develop locked nucleic acid oligonucleotides as orally available therapies for treating inflammatory bowel diseases.

Boehringer Ingelheim and Roche Collaborate on Treatment for Inflammatory Bowel Diseases

Sanofi Genzyme and its partner, Alnylam Pharmaceuticals, have filed a marketing authorization application with EMA for an investigational RNAi therapeutic for treating a genetic-based disease.

Sanofi and Alnylam Seek EMA Approval for RNAi Therapeutic

Company completes first successful run of what is believed to be the largest synthesis-scale done for oligonucleotide APIs.

Nitto Avecia Completes Large-Scale Synthesis of Oligonucleotide

Aikaterini Lalatsa, PhD, is a lecturer in pharmaceutics and drug delivery at the School of Pharmacy and Biomedical Sciences, University of Portsmouth, St Michael’s Building, White Swan Road, Portsmouth PO1 2DT, United Kingdom, email: katerina.lalatsa@port.ac.uk, tel.: +44 (0) 23 9284 3929,

Diana M. Leite is a PhD student at the School of Pharmacy and Biomedical Sciences, University of Portsmouth, St Michael’s Building, White Swan Road, Portsmouth PO1 2DT, United Kingdom.

Nanoparticulate technologies are showing promising potential in delivering both small-molecule drugs and biomacromolecules across the blood brain barrier.

Manufacturing, Nucleic Acids